This study will compare an experimental drug called Z102 (combination of prednisolone and dipyridamole, against prednisone 5mg and prednisone 7.5mg in patients with moderate to severe Rheumatoid Arthritis for a period of 52 weeks.

This is a long-term Phase II safety study of approximately 52 weeks in duration. Eligible patients will have completed at least 6 weeks of Protocol Z102-008 and will have met all inclusion and exclusion criteria for this study.

All patients will be up-titrated on Z102 over 3 weeks or will receive prednisone 5.0 mg or 7.5 mg:

Primary objectives:

Adverse events (AEs)

Vital signs

Clinical laboratory and clinical chemistry evaluations

Secondary objectives:

Joint imaging and bone density

DAS28-CRP and individual components

Patient Global Assessment of Disease Activity

American College of Rheumatology criteria (ACR 20, ACR 50, ACR 70)

Multidimensional Assessment of Fatigue (MAF)

Time to failure

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Have completed all 12 weeks of Protocol Z102-008 or discontinued after participating in at least 6 weeks of the randomized withdrawal portion of Z102-008 for acceptable reasons

Have met all inclusion/exclusion criteria for enrollment into Protocol Z102-008

Have been on DMARD therapy for at least 90 days and have been on a stable DMARD dose without dosage adjustment or modification for 6 weeks prior to enrollment into Protocol Z102-008, and be able to maintain the same dose of conventional DMARD therapy during Protocol Z102-009 participation

Exclusion Criteria:

Did not complete 6 weeks of the double-blind section of Protocol Z102-008, or was discontinued from Protocol Z102-008 for reasons of an AE, protocol violation, or non-compliance

Active cardiovascular disease, unless well controlled by appropriate treatment, for a minimum of 3 months prior to screening for enrollment into Protocol Z102-008

Currently taking aspirin for reasons other than for cardiovascular prophylaxis or their total daily dose is greater than 325 mg

Taking oral steroids at a daily prednisone dose, or the equivalent, of >10 mg/day within the past 2 weeks

Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to entering study Protocol Z102-008 or Protocol Z102-009, at any time during the study, or be anticipated to be given at any time during the study

The need to continue the use of one or multiple NSAIDs at the same time, or use acetaminophen on a chronic basis

All opiate use is prohibited.

Use of any other medications or herbs or non-pharmacological treatments (e.g., acupuncture) used for the treatment of pain is prohibited

Has, or has had, any active severe infections or recent invasive surgical procedures within 30 days of Protocol Z102-008 or Protocol Z102-009 initiation

HIV, hepatitis B, or hepatitis C infection

Has undergone administration of any investigational drug within 30 days of study

All biologic agents are excluded for 90 days prior to Screening and during the conduct of Protocol Z102-008, and Protocol Z102-009

Has undergone administration of rituximab or any B-cell depleting investigational drugs within 6 months of Protocol Z102-008 Screening or Protocol Z102-009 initiation, or at any time during participation in study Protocol Z102-008

Has a history of hypersensitivity reaction to glucocorticoids and/or dipyridamole

Known or suspected history of alcohol or drug abuse within 2 years prior to Screening for Protocol Z102-008

Has any other medical condition which may interfere with the conduct of this study in the opinion of the investigator

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01612377